Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Efficacy of Acipimox in Comparison with Fenofibrate for Hypertriglyceridemia

고중성지방혈증에서 fenofibrate에 대한 acipimox의 효과 비교

  • Kim, Seung Mi (Graduate School of Clinical Pharmacy, Sookmyung Women's University) ;
  • Ji, Eunhee (College of Pharmacy, Gachon University) ;
  • Kim, Hyunah (College of Pharmacy, Ajou University) ;
  • Han, Nayoung (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ;
  • Shim, Mikyung (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ;
  • Shin, Wan Gyoon (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ;
  • Oh, Jung Mi (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University)
  • 김승미 (숙명여자대학교 임상약학대학원) ;
  • 지은희 (가천대학교 약학대학) ;
  • 김현아 (아주대학교 약학대학) ;
  • 한나영 (서울대학교 약학대학 및 종합약학연구소) ;
  • 심미경 (서울대학교 약학대학 및 종합약학연구소) ;
  • 신완균 (서울대학교 약학대학 및 종합약학연구소) ;
  • 오정미 (서울대학교 약학대학 및 종합약학연구소)
  • Received : 2012.06.20
  • Accepted : 2012.09.21
  • Published : 2012.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

목적: 이상지방혈증 환자의 치료는 우선적으로 저밀도지단백을 감소시키고, 저밀도지단백이 목표수치에 도달한 이후에도 혈중 중성지방이 높을 경우 nicotinic acid 또는 fibrate를 사용하도록 권장되고 있다. 본 연구는 이상지방혈증이 있는 환자에서 acipimox의 효과를 fenofibrate와 비교하여 분석하고자 시행되었다. 방법: 본 연구는 서울에 있는 한 3차 대학병원의 환자를 대상으로 후향적으로 의무기록을 분석하여 시행되었다. 혈중 중성지방 농도가 200 mg/dL 이상으로써 acipimox 또는 fenofibrate를 신규처방 받은 환자를 대상으로 각각의 약물이 지단백에 미치는 영향을 36주간 추적하여 비교분석 하였다. 결과: Acipimox를 투여 받은 환자 41명, fenofibrate를 투여 받은 환자 62명이 모집되었으며, 각각의 약물을 복용한 환자군의 기본적인 인구학적인 특성은 유의하게 상이하지 않았다. 3개월 간의 약물투여 후 두 약물군 환자 모두에서 총콜레스테롤(p < 0.05) 및 저밀도지단백(p < 0.001)이 약물투여 전과 비교하였을 때 유의하게 감소하였고, 고밀도지단백은 모든 환자에서 유의하게 증가하였다(p < 0.05). 한편 중성지방 감소율은 acipimox군이 fenofibrate군에서보다 더 크게 나타났다(p < 0.05). 약물유해반응의 빈도는 두 약물군 간에 유의한 차이가 없었다. 결론: 총콜레스테롤, 저밀도지단백 콜레스테롤 등을 감소시키거나 고밀도지단백 콜레스테롤을 증가시키는 효과는 acipimox와 fenofibrate가 유의하게 다르지 않았으며, 중성지방을 감소시키는 효과는 acipimox가 fenofibrate보다 우월하였다.

Keywords

Acknowledgement

Supported by : National Research Foundation of Korea (NRF)

References

  1. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001; 104: 365-372. https://doi.org/10.1161/01.CIR.104.3.365
  2. Castelli WP. Epidemiology of coronary heart disease: the Framingham Study. Am J Med. 1984; 76: 4-12. https://doi.org/10.1016/0002-9343(84)90952-5
  3. Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, Shih J, Stamler J, Wentworth D. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med. 1992; 152: 1490-1500. https://doi.org/10.1001/archinte.1992.00400190110021
  4. Haffner SM. Diabetes, hyperlipidemia, and coronary artery disease. Am J Cardiol. 1999; 83(9B): 17F-21F.
  5. Best JD, O'Neal DN. Diabetic dyslipidaemia: current treatment recommendations. Drugs. 2000; 59: 1101-1111. https://doi.org/10.2165/00003495-200059050-00006
  6. Taskinen MR. Triglyceride is the major atherogenic lipid in NIDDM. Diabetes Metab 1997; 13: 93-98 https://doi.org/10.1002/(SICI)1099-0895(199706)13:2<93::AID-DMR187>3.0.CO;2-6
  7. Musatti L, Maggi E, Moro E, Valzelli G, Tamassia V. Bioavailability and pharmacokinetics in man of acipimox, a new antilipolytic and hypolipemic agent. J Int Med Res. 1981; 9: 381-386. https://doi.org/10.1177/030006058100900515
  8. Lovisolo PP, Briatico-Vangosa G, Orsini G, Ronchi R, Angelucci R, Valzelli G. Pharmacological profile of a new anti-lipolytic agent: 5-methyl-pyrazine-2-carbozylic acid 4-oxide(Acipimox)(1)I-Mechanism of action. Pharmacol Res Commun. 1981; 13: 151-161. https://doi.org/10.1016/S0031-6989(81)80016-1
  9. Lovisolo PP, Briatico-Vangosa G, Orsini G, Ronchi R, Angelucci R. Pharmacological profile of a new anti-lipolytic agent: 5-methyl-pyrazine-2-carbozylic acid 4-oxide (Acipimox) (1)II-Antilipolytic and blood lipid lowering activity. Pharmacol Res Commun. 1981; 13: 163-174. https://doi.org/10.1016/S0031-6989(81)80017-3
  10. Seed M, O'Connor B, Perombelon N, O'Donnell M, Reaveley D, Knight BL. The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. Atherosclerosis. 1993; 101: 61-68. https://doi.org/10.1016/0021-9150(93)90102-Z
  11. Lintott CJ, Scott RS, Bremer JM. Treatment of hyperlipidaemia with acipimox. Curr Med Res Opin. 1989; 11: 374-379. https://doi.org/10.1185/03007998909110138
  12. Saloranta C, Groop L, Ekstrand A, Franssila-Kallunki A, Eriksson J, Taskinen MR. Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes. Diabet Med. 1993; 10: 950-957 https://doi.org/10.1111/j.1464-5491.1993.tb00011.x
  13. Vaag AA, Beck-Nielsen H. Effects of prolonged acipimox treatment on glucose and lipid metabolism and on in vivo insulin sensitivity in patients with non-insulin dependent diabetes mellitus. Acta Endocrinol(Copenh). 1992; 127: 344-350
  14. Otto C, Parhofer KG, Ritter MM, Richter WO, Schwandt P. Effects of acipimox on haemorheology and plasma lipoproteins in patients with mixed hyperlipoproteinaemia. Br J Clin Pharmacol. 1998; 46: 473-478.
  15. Sirtori CR, Gianfranceschi G, Sirtori M, et al., Reduced triglyceridemia and increased high density lipoprotein cholesterol levels after treatment with acipimox, a new inhibitor of lipolysis. Atherosclerosis. 1981; 38: 267-271. https://doi.org/10.1016/0021-9150(81)90042-3
  16. Shin KC, Kwok CF, Hwu CM, et al., Acipimox attenuates hypertriglyceridemia in dyslipidemic noninsulin dependent diabetes mellitus patients without perturbation of insulin sensitivity and glycemic control. Diabetes Res Clin Pract. 1997; 36: 113-119. https://doi.org/10.1016/S0168-8227(97)00039-9
  17. Guay DR. Micronized fenofibrate: a new fibric acid hypolipidemic agent. Ann Pharmacother. 1999; 33: 1083-1103. https://doi.org/10.1345/aph.18432
  18. Munoz A, Guichard JP, Reginault P. Micronized fenofibrate. Atherosclerosis. 1994; 110(Suppl): S45-S48. https://doi.org/10.1016/0021-9150(94)05375-S
  19. Shepherd J. Mechanism of action of fibrates. Postgrad Med J. 1993; 69(Suppl1): S34-S41.
  20. Austin MA et al., Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998; 81(4A): 7B-12B. https://doi.org/10.1016/S0002-9149(98)00031-9
  21. SeongOk Kim. Medication Adherence of Elderly with Hypertension and/or Diabetes-mellitus and its' Influencing Factors. Kor J Clin Pharm. 2011; 21(2): 81-89.